Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (8)

2023

  1. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

2021

  1. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

    BMC Health Services Research, Vol. 21, Núm. 1

2020

  1. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

2019

  1. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2014

  1. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience

    Annals of Hematology, Vol. 93, Núm. 9, pp. 1551-1558

2009

  1. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer

    Breast Journal